Leukotriene receptor antagonist pranlukast suppresses eosinophil infiltration and cytokine production in human nasal mucosa of perennial allergic rhinitis

Annals of Otology, Rhinology and Laryngology

Volumn 112, Issue 11, 2003, Pages 955-961

  Ueda, Tsutomu ^a   Takeno, Sachio ^a   Hirakawa, Katsuhiro ^a   Furukido, Kyosuke ^a   Yajin, Koji ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Allergic rhinitis; Cysteinyl leukotrienes; Eosinophilic inflammation; Pranlukast; T helper type 2 cytokine; Th2 type cytokine

Indexed keywords

CYTOKINE; EOSINOPHIL CATIONIC PROTEIN; EOSINOPHIL CATIONIC PROTEIN 2; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 8; LEUKOCYTE ELASTASE; LEUKOTRIENE RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; PEPTIDOLEUKOTRIENE; PRANLUKAST; RANTES; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ALLERGIC RHINITIS; ARTICLE; CELL INFILTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG RECEPTOR BINDING; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL; FACIAL BONE; FEMALE; HUMAN; HUMAN CELL; INFLAMMATION; INFLAMMATORY CELL; MALE; NOSE MUCOSA; PRIORITY JOURNAL; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 0242678484     PISSN: 00034894     EISSN: None     Source Type: Journal    
DOI: 10.1177/000348940311201107     Document Type: Article

References (43)

1. Shaw RJ, Fitzharris P, Cromwell O, Wardlaw AJ, Kay AB. Allergen-induced release of sulphidopeptide leukotrienes (SRS-A) and LTB4 in allergic rhinitis. Allergy 1985;40:1-6.
2. Bisgaard H, Olsson P, Bende M. Leukotriene D4 increases nasal blood flow in humans. Prostaglandins 1984;27:599-604.
3. Bisgaard H, Olsson P, Bende M. Effect of leukotriene D4 on nasal mucosal blood flow, nasal airway resistance and nasal secretion in humans. Clin Allergy 1986;16:289-97.
4. Laitinen LA, Laitinen A, Haahtela T, Vilkka V, Spur BW, Lee TH. Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet 1993;341:989-90.
5. Taki F, Suzuki R, Torii K, Matsumoto S, Taniguchi H, Takagi K. Reduction of the severity of bronchial hyperresponsiveness by the novel leukotriene antagonist 4-oxo-8-[4-(4-phenyl-butoxy)benzoylamino]-2-(tetrazol-5-yl)-4H-1-benzopyran hemihydrate. Arzneimittelforschung 1994;44:330-3.
6. Taniguchi Y, Tamura G, Honma M, et al. The effect of an oral leukotriene antagonist, ONO-1078, on allergen-induced immediate bronchoconstriction in asthmatic subjects. J Allergy Clin Immunol 1993;92:507-12.
7. Tomari S, Shimoda T, Kawano T, et al. Effects of pranlukast, a cysteinyl leukotriene receptor 1 antagonist, combined with inhaled beclomethasone in patients with moderate or severe asthma. Ann Allergy Asthma Immunol 2001;87:156-61.
8. Shirasaki H, Asakura K, Narita S, Kataura A. The effect of a cysteinyl leukotriene antagonist, ONO-1078 (pranlukast) on agonist- and antigen-induced nasal microvascular leakage in guinea pigs. Rhinology 1998;36:62-5.
9. Benson M, Strannegard IL, Strannegard O, Wennergren G. Topical steroid treatment of allergic rhinitis decreases nasal fluid TH2 cytokines, eosinophils, eosinophil cationic protein, and IgE but has no significant effect on IFN-γ, IL-1β TNF-α, or neutrophils. J Allergy Clin Immunol 2000;106:307-12.
10. Rissoan MC, Soumelis V, Kadowaki N, et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science 1999;283:1183-6.
11. Leung DY. Molecular basis of allergic diseases. Mol Genet Metab 1998;63:157-67.
12. Okuda M. A survey of rhinitis in Japan and an evaluation of the treatment with sodium cromoglycate. Rhinology 1982;20:63-72.
13. Numata T, Konno A, Yamakoshi T, Hanazawa T, Terada N, Nagata H. Comparative role of peptide leukotrienes and histamine in the development of nasal mucosal swelling in nasal allergy. Ann Otol Rhinol Laryngol 1999;108:467-73.
14. Okuda M, Watase T, Mezawa A, Liu CM. The role of leukotriene D4 in allergic rhinitis. Ann Allergy 1988;60:537-40.
15. Mizutani N, Nabe T, Imai A, Sakurai H, Takenaka H, Kohno S. Markedly increased nasal blockage by intranasal leukotriene D4 in an experimental allergic rhinitis model: contribution of dilated mucosal blood vessels. Jpn J Pharmacol 2001;86:170-82.
16. Okuda M, Kataura A, Togawa K, et al. Clinical evaluation of leukotriene antagonist: ONO-1078 (pranlukast hydrate), on perennial allergic rhinitis. A double-blind, comparative study with epinastine hydrochloride (phase III study) [in Japanese]. Otologia Fukuoka 1998;44:47-72.
17. Philip G, Malmstrom K, Hampel FC, et al. Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy 2002;32:1020-8.
18. Pullerits T, Praks L, Ristioja V, Lotvall J. Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 2002;109:949-55.
19. Donnelly AL, Glass M, Minkwitz MC, Casala TB. The leukotriene D4-receptor antagonist, ICI 204,219, relieves symptoms of acute seasonal allergic rhinitis. Am J Respir Crit Care Med 1995;151:1734-9.
20. Shirasaki H, Kanaizumi E, Watanabe K, et al. Expression and localization of the cysteinyl leukotriene 1 receptor in human nasal mucosa. Clin Exp Allergy 2002;32:1007-12.
21. Bruijnzeel PL, Rihs S, Betz S. Eosinophilic granulocytes and their significance in allergic diseases [in German]. Schweiz Med Wochenschr 1992;122:173-80.
22. Thivierge M, Doty M, Johnson J, Stankova J, Rola-Pleszczynski M. IL-5 up-regulates cysteinyl leukotriene 1 receptor expression in HL-60 cells differentiated into eosinophils. J Immunol 2000;165:5221-6.
23. Bentley AM, Meng Q, Robinson DS, Hamid Q, Kay AB, Durham SR. Increases in activated T lymphocytes, eosinophils, and cytokine mRNA expression for interleukin-5 and granulocyte/macrophage colony-stimulating factor in bronchial biopsies after allergen inhalation challenge in atopic asthmatics. Am J Respir Cell Mol Biol 1993;8:35-42.
24. Venge P. Eosinophil activity in bronchial asthma. Allergy Proc 1994;15:139-41.
25. Kita H, Abu-Ghazaleh RI, Sur S, Gleich GJ. Eosinophil major basic protein induces degranulation and IL-8 production by human eosinophils. J Immunol 1995;154:4749-58.
26. Bisgaard H. Pathophysiology of the cysteinyl leukotrienes and effects of leukotriene receptor antagonists in asthma. Allergy 2001;56(suppl 66):7-11.
27. Nagata M, Saito K, Tsuchiya K, Sakamoto Y. Leukotriene D4 upregulates eosinophil adhesion via the cysteinyl leukotriene 1 receptor. J Allergy Clin Immunol 2002;109:676-80.
28. Spada CS, Nieves AL, Krauss AH, Woodward DF. Comparison of leukotriene B4 and D4 effects on human eosinophil and neutrophil motility in vitro. J Leukoc Biol 1994;55:183-91.
29. Underwood DC, Osborn RR, Newsholme SJ, Torphy TJ, Hay DW. Persistent airway eosinophilia after leukotriene (LT) D4 administration in the guinea pig: modulation by the LTD4 receptor antagonist, pranlukast, or an interleukin-5 monoclonal antibody. Am J Respir Crit Care Med 1996;154:850-7.
30. Hojo M, Suzuki M, Maghni K, Hamid Q, Powell WS, Martin JG. Role of cysteinyl leukotrienes in CD4(+) T cell-driven late allergic airway responses. J Pharmacol Exp Ther 2000;293:410-6.
31. Yoshida S, Ishizaki Y, Shoji T, et al. Effect of pranlukast on bronchial inflammation in patients with asthma. Clin Exp Allergy 2000;30:1008-14.
32. Pizzichini E, Leff JA, Reiss TF, et al. Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. Eur Respir J 1999;14:12-8.
33. Tohda Y, Nakahara H, Kubo H, Haraguchi R, Fukuoka M, Nakajima S. Effects of ONO-1078 (pranlukast) on cytokine production in peripheral blood mononuclear cells of patients with bronchial asthma. Clin Exp Allergy 1999;29:1532-6.
34. Uno T, Tanaka H, Nagai H. Cysteinyl leukotrienes do not mediate lipopolysaccharide-induced airway hyperresponsiveness in guinea pigs. Prostaglandins 1996;52:447-61.
35. Knani J, Campbell A, Enander I, Peterson CGB, Michel FB, Bousquet J. Indirect evidence of nasal inflammation assessed by titration of inflammatory mediators and enumeration of cells in nasal secretions of patients with chronic rhinitis. J Allergy Clin Immunol 1992;90:880-9.
36. Cassatella MA. The production of cytokines by polymorphonuclear neutrophils. Immunol Today 1995;16:21-6.
37. Haziot A, Tsuberi BZ, Goyert SM. Neutrophil CD14: biochemical properties and role in the secretion of tumor necrosis factor-alpha in response to lipopolysaccharide. J Immunol 1993;150:5556-65.
38. Shute J. Interleukin-8 is a potent eosinophil chemo-attractant. Clin Exp Allergy 1994;24:203-6.
39. Sanz MJ, Weg VB, Bolanowski MA, Nourshargh S. IL-1 is a potent inducer of eosinophil accumulation in rat skin. Inhibition of response by a platelet-activating factor antagonist and an anti-human IL-8 antibody. J Immunol 1995;154:1364-73.
40. Horie S, Gleich GJ, Kita H. Cytokines directly induce degranulation and superoxide production from human eosinophils. J Allergy Clin Immunol 1996;98:371-81.
41. Godding V, Stark JM, Sedgwick JB, Busse WW. Adhesion of activated eosinophils to respiratory epithelial cells is enhanced by tumor necrosis factor-alpha and interleukin-1 beta. Am J Respir Cell Mol Biol 1995;13:555-62.
42. Gundel RH, Wegner CD, Torcellini CA, et al. Endothelial leukocyte adhesion molecule-1 mediates antigen-induced acute airway inflammation and late-phase airway obstruction in monkeys. J Clin Invest 1991;88:1407-11.
43. Ishizaka A, Hasegawa N, Sakamaki F, et al. Effects of ONO-1078, a peptide leukotriene antagonist, on endotoxin-induced acute lung injury. Am J Respir Crit Care Med 1994;150:1325-31.